Physician profile
Stephanie Rutledge
NPI 1437504917
$2,373.20
in general payments reported to CMS, 2019-2025
10 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $238 · 2021: $342 · 2022: $139 · 2023: $229 · 2024: $1,265 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $880 · Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $880.00 |
| Food and Beverage | $774.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $993.38 | 2024 | |
| Janssen Biotech, INC. | $316.00 | 2020-2021 | |
| Gilead Sciences, INC. | $297.43 | 2022-2024 | |
| Boston Scientific Corporation | $194.93 | 2023-2024 | Resolution 360 Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $142.58 | 2021-2024 | Entyvio |
| Qol Medical, LLC | $138.88 | 2020 | |
| Mallinckrodt Hospital Products INC. | $118.73 | 2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.64 | 2024 | Xifaxan |
| Abbvie INC. | $35.36 | 2024-2025 | |
| Lilly USA, LLC | $27.27 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Rutledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.